Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
In a recent paper in Movement Disorders, researchers sought to better understand SWEDDs compared to people with Parkinson’s and healthy controls (HCs) by comparing the nonmotor symptoms for each group using the PPMI baseline data. Certain symptoms, like orthostatic hypotension, were found to be more common in SWEDDs than in PD participants.
The PPMI prodromal cohort, genetic cohort, and genetic registry data is now live and available for download in the PPMI database. Read more about these cohorts and access this data.
In a paper published in Movement Disorders, Weintraub, et al. investigate the prevalence of cognitive impairment and neuropsychiatric symptoms (NPS), such as depression, apathy, and anxiety, in early, unmedicated people with Parkinson’s compared with healthy controls (HCs) using the PPMI baseline data.
PPMI is headed to the American Academy of Neurology (AAN) 2015 Annual Meeting, taking place in Washington D.C. from April 18 through April 25. Top players in neurology will come together to learn about the latest in research, showcased through presentations and posters, including several featuring PPMI data.
The PPMI Genetics Core has just made their whole exome sequencing data live in the PPMI database. This sequencing targeted 201,121 Exons, UTRs, and miRNA in DNA from whole-blood from the original PPMI cohort of over 600 PD, SWEDD, and control subjects. Read more about the analysis and learn how to access the data.